Thomas Taapken
Director of Finance/CFO at INFLARX N.V.
Net worth: 4 865 $ as of 30/04/2024
Thomas Taapken active positions
Companies | Position | Start | End |
---|---|---|---|
SCIBASE HOLDING AB (PUBL) | Director/Board Member | 16/05/2017 | - |
Independent Dir/Board Member | 16/05/2017 | - | |
INFLARX N.V. | Director of Finance/CFO | 01/10/2020 | - |
elbion NV
elbion NV Pharmaceuticals: MajorHealth Technology Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium. | Director of Finance/CFO | - | - |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | Chairman | 01/01/2019 | - |
Bluehaven Therapeutics AG | Chief Executive Officer | - | - |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Director/Board Member | 01/01/2021 | - |
Independent Dir/Board Member | 01/01/2021 | - | |
Scibase AB | Director/Board Member | 01/01/2017 | - |
Career history of Thomas Taapken
Former positions of Thomas Taapken
Companies | Position | Start | End |
---|---|---|---|
MEDIGENE AG | Chief Executive Officer | 01/01/2017 | 31/08/2018 |
Director of Finance/CFO | 01/01/2017 | 31/08/2018 | |
EPIGENOMICS AG | Chief Executive Officer | 01/04/2011 | 30/06/2016 |
Director of Finance/CFO | 01/06/2011 | 30/06/2016 | |
Investor Relations Contact | 01/04/2011 | 30/06/2016 | |
░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░ ░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░ ░░░░░░░░ ░░░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Training of Thomas Taapken
Technical University of Berlin | Doctorate Degree |
Statistics
International
Germany | 10 |
Belgium | 3 |
Sweden | 3 |
Operational
Director of Finance/CFO | 6 |
Chief Executive Officer | 4 |
Director/Board Member | 4 |
Sectoral
Health Technology | 11 |
Finance | 3 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 4 |
---|---|
EPIGENOMICS AG | Health Technology |
MEDIGENE AG | Health Technology |
SCIBASE HOLDING AB (PUBL) | Health Technology |
INFLARX N.V. | Health Technology |
Private companies | 11 |
---|---|
elbion NV
elbion NV Pharmaceuticals: MajorHealth Technology Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium. | Health Technology |
elbion AG
elbion AG Miscellaneous Commercial ServicesCommercial Services elbion AG discovers and develops new small molecule drugs for the treatment of inflammatory and central nervous system diseases with high unmet medical need. It's lead product candidate AWD 12-281 is a topical inhibitor and is in phase IIa trials for the treatment of chronic obstructive pulmonary disease and has licensed it to GlaxoSmithKline for exclusive development and commercialization. It focuses on target areas, including PDE inhibitors and CNS modulators, in terms of novel chemistries, novel assays and mechanisms of action, as well as in-house animal disease models. Founded in 2002, the company is headquartered in Radebeul, Germany. | Commercial Services |
Sanofi-Aventis Deutschland GmbH
Sanofi-Aventis Deutschland GmbH Pharmaceuticals: MajorHealth Technology Sanofi-Aventis Deutschland GmbH engages in the development, manufacture, and packaging of medicines, as well as pharmaceutical products. It also focuses on the research into the causes of diseases and the search for its drug treatment. The company was founded in 2004 and is headquartered in Frankfurt, Germany. | Health Technology |
DVC Deutsche Venture Capital
DVC Deutsche Venture Capital Investment ManagersFinance DVC Deutsche Venture Capital (DVC) is an independent venture capital firm focused on science-based sectors. DVC was established in 1998 and is based in Munich. The firm operates in partnership with Deutsche Bank AG (FR: DBK; NYSE: DB). | Finance |
Biotie Therapies Oy
Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland. | Health Technology |
Burrill LLC
Burrill LLC Investment ManagersFinance Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California. | Finance |
Immunic AG
Immunic AG Pharmaceuticals: MajorHealth Technology Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany. | Health Technology |
ImCyse SA
ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | Health Technology |
Bluehaven Therapeutics AG | |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Health Technology |
Scibase AB |
- Stock Market
- Insiders
- Thomas Taapken
- Experience